

REMARKS

Applicant thanks the Examiner and the Examiner's supervisor for the courtesy extended to Applicant's attorney during the interview held February 22, 2007, in the above-identified application. During the interview, Applicant's attorney explained the presently-claimed invention and why it is patentable over the applied prior art, and discussed other issues raised in the Office Action. The discussion is summarized and expanded upon below.

The rejection of Claims 1-18 under 35 U.S.C. § 102(b) as anticipated by or, in the alternative, under 35 U.S.C. § 103(a) as obvious over, US 5,911,979 (Midha et al), is respectfully traversed.

Midha et al is drawn to an aqueous hair setting composition containing a particular silicone macromer-grafted copolymer as a hair setting agent (column 2, line 44 ff), which composition may optionally contain an organic oil conditioning agent (column 21, line 10 ff), which conditioning agent may be, *inter alia*, an ethylene glycol mono- or di-fatty acid ester, a diethylene glycol mono- or di-fatty acid ester, or a polyethylene glycol mono- or di-fatty acid ester (column 22, lines 40-43). Midha et al discloses other conditioning agents, such as hydrocarbon oils and (non-alkylene glycol) fatty esters, and esters of glycerol, with various carbon chain length ranges disclosed, but no carbon chain length range is disclosed for the above-discussed alkylene glycol esters. Midha et al discloses further that the pH of their compositions is generally between about 3 and about 9, preferably between about 4 and about 8 (column 23, lines 24-26).

As stated in *In re Arkley*, 455 F.2d 586, 587, 172 USPQ 524, 526 (CCPA 1972) (**copy enclosed**):

[R]ejections under 35 U.S.C. 102 are proper only when the claimed subject matter is identically disclosed or described in "the prior art." Thus, for the instant rejection under 35 U.S.C. [102(b)] to have been proper, the . . . reference must clearly and unequivocally disclose the claimed [subject matter] or direct those skilled in the art to the [subject matter] without any need for picking, choosing, and combining various disclosures not directly related to each other by the teachings of the cited reference.

Such picking and choosing may be entirely proper in the making of a 103, obviousness rejection, where the applicant must be afforded an opportunity to rebut with objective evidence any inference of obviousness which may arise from the similarity of the subject matter which he claims to the prior art, but it has no place in the making of a 102, anticipation rejection.

Midha et al does not anticipate the presently-claimed invention. Independent Claim 2 requires that the pH of the composition be 1 to 5 at 25°C **when diluted to 20 times the weight with water** (emphasis added). Clearly, and as Applicant's attorney pointed out during the above-referenced interview, the pH of the composition recited in Claim 2 would be significantly lower prior to dilution with 20 times the weight with water. On the contrary, if the pH of the composition disclosed by Midha et al were diluted with 20 times its weight with water, the pH would be significantly higher than the minimum recited pH of about 3.

In addition, Claim 2, in its broadest embodiment, requires at least two different fatty acid constituents, including at least 65 wt.% of fatty acids having 18 or more carbon atoms and no more than 5 wt.% of fatty acids having less than 16 carbon atoms. As discussed above, and as Applicant's attorney noted during the above-referenced interview, Midha et al discloses **no** carbon chain length recitation for the fatty acid used to make their alkylene glycol esters.

Thus, Midha et al does not satisfy the *Arkley* test. At best, Midha et al is available under 35 U.S.C. § 103(a) only.

As described in the specification at the paragraph bridging pages 1 and 2, alkylene glycol mono- or di-alkyl esters are known as a pearling substance, but such esters as used in the prior art have been problematical. Applicant has discovered that when the carbon chain length of the fatty acid used to make the esters is within the range of above-discussed Claim 2, superior results are obtained with regard to at least the properties of elegance of appearance, stability under acidic conditions, and elegance of appearance after storage, as Applicant's attorney pointed out during the interview.. The criteria for evaluation of these


properties, as well as Examples 1-6, which are examples according to the presently-claimed invention, and Comparative Examples 1 and 2, which are for purposes of comparison, are described in the specification beginning at page 9, line 6. The data is shown in Table 1, at page 11 of the specification. As the data show, all of the examples received the highest grade of "A" for the above-discussed criteria, while the comparative examples all received a grade of "C". In addition, the comparative examples are much closer to the presently-claimed invention than Midha et al. Indeed, the only difference between the examples and the comparative examples are, the relative amounts of fatty acid chain lengths for the fatty acids making up the recited long-chain fatty acid glycol esters herein. Thus, while Claim 1 herein requires a minimum of 60 wt.% for fatty acids having 18 or more carbon atoms, Comparative Examples 1 and 2 contain a corresponding percent of 50 wt.%. Compare *Ex parte Humber*, 217 USPQ 265 (Bd. Pat. App. & Inter. 1981) (**copy enclosed**) (comparative data showing the claimed chlorine-containing compounds to be unexpected over various (non-prior art) chlorine-containing isomers was accepted as more probative over prior art, drawn to non-chlorine containing analogs of the claimed compounds, asserted to be closest.)

For all the above reasons, it is respectfully requested that this rejection be withdrawn.

Applicant respectfully submits that all of the present claims in this application are in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Harris A. Pitlick
Registration No. 38,779

Customer Number
22850
Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 03/06)
NFO:HAP\smi

FULL TEXT OF CASES (USPQ FIRST SERIES)

In re Arkley, Eardley, and Long, 172 USPQ 524 (CCPA 1972)

In re Arkley, Eardley, and Long, 172 USPQ 524 (CCPA 1972)

In re Arkley, Eardley, and Long

(CCPA)

172 USPQ 524

Decided Feb. 17, 1972

No. 8553

U.S. Court of Customs and Patent Appeals

Headnotes

PATENTS

1. Patentability - Anticipation - In general (§ 51.201)

Patentability - Invention - In general (§ 51.501)

Fact that rejections under 35 U.S.C. 103 are proper where subject matter claimed "is not identically disclosed or described" in prior art indicates that rejections under section 102 are proper only when claimed subject matter is identically disclosed or described in prior art.

2. Court of Customs and Patent Appeals - In general (§ 28.01)

Court does not grant patent where it reverses rejection of claim; it is Patent Office which grants patents, not the court.

3. Court of Customs and Patent Appeals - In general (§ 28.01)

Pleading and practice in Patent Office - Rejections (§ 54.7)

Court's reversal of rejection of claim on ground that it is anticipated by reference under 35 U.S.C. 102 leaves Patent Office free to reject claim as obvious under section 103 in view of reference since such latter rejection was not before court.

4. Court of Customs and Patent Appeals - Weight given decisions below (§ 28.35)

It is not court's practice to apply a different standard in cases in complex areas of technology than it does in easily understood cases.

Particular patents-Cephaloridine

Arkley, Eardley, and Long, Cephaloridine, rejection of claim 30 reversed.

Case History and Disposition:

Page 524

Appeal from Board of Appeals of the Patent Office.

Application for patent of Vincent Arkley, Stephen Eardley, and Alan Gibson Long, Serial No. 329,212, filed Dec. 9, 1963; Patent Office Group 120. From decision rejecting claim 30, applicants appeal. Reversed; Baldwin, Judge, concurring with opinion in which

Page 525

Almond, Judge, joins; Worley, Chief Judge, dissenting with opinion.

Attorneys:

J. William Pike and Bacon & Thomas, both of Washington, D. C. (Fred T. Williams, John J. Cavanaugh, and Pendleton, Neuman, Williams & Anderson of counsel) for appellants.

S. Wm. Cochran (Jack E. Armore and Henry Willard Tarring II of counsel) for Commissioner of Patents.

Judge:

Before Worley, Chief Judge, and Rich, Almond, Baldwin, and Lane, Associate Judges.

Opinion Text

Opinion By:

Rich, Judge.

This appeal is from the decision of the Patent Office Board of Appeals affirming the rejection of claim 30 in appellants' application serial No. 329,212, filed December 9, 1963, for a cephalosporin-type antibiotic known as cephaloridine. No claim has been allowed. We reverse.

The Subject Matter Claimed

The appealed claim is drawn to a single compound, by structural formula, and reads:

30. A compound of the formula

Graphic material consisting of a chemical formula or diagram set at this point is not available. See text in hard copy or call BNA PLUS at 1-800-452-7773 or 202-452-4323.

This compound is said to be a broad spectrum antibiotic, effective against both gram-positive and gram-negative micro-organisms, and to possess many other virtues not relevant here because of the nature of the rejection.

The Rejection

Appellants' claim has been rejected as *anticipated* by U. S. patent No. 3,218,318; issued to Edwin H. Flynn November 16, 1965, on an application filed in the United States August 31, 1962, and

available against appellants' application by virtue of 35 U.S.C. 102(e) as of its filing date. This reference discloses generically a class of cephalosporin-type compounds having the following structural formula:

Graphic material consisting of a chemical formula or diagram set at this point is not available. See text in hard copy or call BNA PLUS at 1-800-452-7773 or 202-452-4323.

in which R₁, taken alone, is -OH, C₁-C₈ acyloxy, or tertiary-amino; R₂ is -OH when R₁ is -OH, R₂ is -OH when R₁ is C₁-C₈ acyloxy, R₂ is -O- when R₁ is tertiary-amino, R₁ and R₂, when taken together, are -O-, n is zero or 1, R₃ is C₁-C₆ alkylene, and R₄ is a heteromonocyclic radical containing O, S, and/or N. Appellants "conservatively" estimate that over 230,000 compounds (including, concededly, theirs) are embraced within this generic disclosure, and the board in turn conceded that, "If this were the only anticipatory disclosure in the reference," the disclosure would be "too diffuse" to support a 102 rejection.

However, the board found: (1) that Flynn's examples 4 and 10 "adequately disclose the exact precursors of the presently claimed compound"; (2) that Flynn's statement that

Cephalosporin C is also readily converted into compounds of the cephalosporin C_A

Page 526

type by refluxing in aqueous solution with an excess of pyridine, for example, as described in Belgian Patent 593,777.

was adequate to teach how to convert the C-type precursors disclosed in examples 4 and 10 to the C_A-type compound claimed by appellants; and (3) that Flynn's statement that, "in general, those compounds which possess the cephalosporin C_A nucleus are more effective antibacterially than those containing the cephalosporin C nucleus" provided the "motive * * * to follow this additional teaching * * *." Putting these three findings together, the board held that

The indicated combination of Example 4 or 10 with * * * [the teaching of how to convert "Cephalosporin C * * * into compounds of the cephalosporin C_A type"] is not a matter of obviousness within the meaning of 35 U.S.C. 103 but of direct teaching within the four corners of the patent.

The effect of this holding, of course, was that the board did not have to look at the extensive objective evidence which appellants had offered to rebut any inference of obviousness which might be thought to arise from the teachings of the Flynn patent.

Opinion

[1] The sole issue in this case is whether cephaloridine is "described" in the Flynn patent within the meaning of that word in 35 U.S.C. 102(e). ¹It is to be noted that rejections under 35 U.S.C. 103 are proper where the subject matter claimed "is not *identically* disclosed or described" (emphasis ours) in "the prior art," indicating that rejections under 35 U.S.C. 102 are proper only when the claimed subject matter *is* identically disclosed or described in "the prior art." Thus, for the instant rejection under 35 U.S.C. 102(e) to have been proper, the Flynn reference must clearly and unequivocally disclose the claimed compound or direct those skilled in the art to the compound without *any* need for picking, choosing, and combining various disclosures not directly related to each other by the teachings of the cited reference. Such picking and choosing may be entirely proper in the making of a 103, obviousness rejection, where the applicant must be afforded an opportunity to rebut with objective evidence any inference of obviousness which may arise from the *similarity* of the subject matter which he claims to the prior art, but it has no place in the making of a 102, anticipation

rejection.

In this case we have no difficulty in deciding that the portions of the Flynn reference relied upon by the Patent Office do not identically describe the claimed subject matter. As appellants point out, the compounds of Flynn's examples 4 and 10 are the "exact precursors" of appellants' compound "only to the extent that appellants have discovered that cephaloridine will be formed *if* the acid [disclosed in example 10] is first selected and *then* carefully reacted with a particular tertiary amine *which also must be selected*." (Emphasis in original.) Of course, it does appear that the "particular tertiary amine" to which appellants refer is pyridine, which is mentioned elsewhere in Flynn as an example of the class of reactants ²with which a particular cephalosporin C-type compound (namely, cephalosporin C itself) may be converted into compounds of the cephalosporin C_A type, but there is nothing in the teachings relied upon by the Patent Office which "clearly and unequivocally" directs those skilled in the art to make this selection nor any indication that Flynn ever made the selection himself. Similarly, while it is reasonable to suppose that Flynn's teaching that "in general, those compounds which possess the cephalosporin C_A nucleus are more effective antibacterially than those

Page 527

containing the cephalosporin C nucleus" would provide some "motive" for those that followed him to concentrate their investigations on compounds possessing the cephalosporin C_A nucleus, that motivation is a very general one, pointing to no particular one of the myriads of compounds, actual and potential, containing the cephalosporin C_A nucleus.

The board, apparently recognizing the weakness of its position in attempting to arrive at an anticipation by combining the disclosures in examples 4 and 10 with the above-quoted teaching elsewhere in the patent of how to convert a particular, different cephalosporin C-type compound into cephalosporin C_A-type compounds, postulates certain teachings which might have been in the reference patent any one of which, according to it, if present would have removed all doubt concerning the completeness of the anticipation. ³The simple answer to the board's argument is that these teachings were not contained in the Flynn patent and that we do not regard the teachings which were there and which *were* relied upon below as the equivalent of those which were postulated by the board. We do not read into references things that are not there.

Although the board declined to discuss four relatively recent decisions by this court in cases involving description requirements in various sections of the patent statute ⁴on the ground that "the issue [of anticipation] is essentially a factual one," it did consider the older case of *In re Armstrong*, 47 CCPA 1084, 280 F.2d 132, 126 USPQ 281 (1960), to be "apposite on this point." There this court reversed the board, finding support for process claims reciting the use of sodium carbonate although the example in the specification advanced as support for the claims used sodium hydroxide. However, in the first place, the *Armstrong* case was decided well before the line of cases beginning with *Ruschig II*, *supra*, ⁵which have significantly tightened up on the application of the description requirement in the first paragraph of 35 U.S.C. 112, and, in the second place, the opinion in *Armstrong* points out that appellants' specification stated that alkali hydroxides and alkali carbonates could be used "interchangeably" in their process. The opinion stresses this equivalency, which involved a tiny number of variables in comparison to the situation here. There are no equivalent "blaze marks," to quote the language of *Ruschig II*, in the case at hand.

Accordingly, we will not sustain the rejection on the ground on which it was made. Concerning the rejection as it is reformulated by the dissent, we express no opinion. It may be that the Patent Office *should* have relied upon the portions of Flynn on which the dissent relies, or it may be that they had very good reasons for not doing so. In any event, they did *not* rely on those teachings in Flynn, and appellants have therefore had no opportunity to comment thereon. We do not conceive that it is part

of our duty to make better rejections for the Patent Office, even if we could be sure that we really were making a "better rejection," nor do we think that it would be consistent with the requirements of due process for us to do so for the first time on appeal, without notice to the affected party.

[2] Furthermore, we point out that we are not granting appellants a patent, if that is what the dissent means by "bestowing on the applicants a license to litigate." We are simply reversing a rejection on the ground that the claim on appeal is *anticipated* under § 102 by Flynn. It may well be that it is unpatentable because *obvious* under § 103 in view of Flynn,

[3] but no such rejection is before us. The Patent Office is free to make such a rejection after our decision in this case should it think it appropriate. In *re* Ruschig, 54 CCPA 1551, 379 F.2d 990, 154 USPQ 118 (1967); and In *re* Fisher, 58 CCPA —, 448 F.2d 1406, 171 USPQ 292 (1971). In any event, it is the Patent Office which grants patents, not this

[4] court. It may further be observed that

Page 528

it is not now the practice in this court, if it ever was, to apply a different standard in cases which are in "complex areas of technology" than we do in easily understood cases.

The decision of the board is *reversed*.

Footnotes

Footnote 1. At one time appellants contended that Flynn was not an "enabling disclosure," In *re* LeGrice, 49 CCPA 1124, 301 F.2d 929, 133 USPQ 365 (1962), but we gather that they have abandoned that contention on appeal, although there is still an ambiguous reference to LeGrice in their briefs.

Footnote 2. The parties argue, in essence, about whether the words "for example" in the sentence "Cephalosporin C is also readily converted into compounds of the cephalosporin C A type by refluxing in aqueous solution with an excess of pyridine, for example, as described in Belgian Patent 593,777" refers to the word "pyridine" or the words "as described." Appellants argue that "it is to be stressed that pyridine is only being suggested as an *example* of the tertiary amine[s] suitable for the reaction with the prior art compound cephalosporin C," while the solicitor seems to be taking the position that Flynn's specification would be read as indicating that the Belgian patent was one place among many where those skilled in the art could learn how to react cephalosporin C with pyridine. While the matter is not free from doubt, we think it more likely that the sentence would be read in the former way because the presence of the word "type" after "C A" and not after "C" suggests that one particular C-type compound (namely, cephalosporin C itself) can be changed into *various* C A-type compounds by refluxing it with an excess of the proper reactant. This interpretation of the controverted sentence is reinforced by the next sentence in Flynn's specification, which is as follows:

The reaction is applicable in general to the tertiary amines, of which numerous examples are given above, yielding corresponding derivatives of the cephalosporin C A type wherein the tertiary amine is attached to the methyl group in the 3 position of the thiazine ring, and forms an inner salt with the carboxyl group in the 4 position.

Footnote 3. These postulations were contained in the following passage from the board's opinion:

There would be no doubt of the completeness of the anticipation if, paraphrasing column 3, lines 47 to 50, the following language were present at the end of each of Examples 4 and 10:

"This compound is also readily converted into a compound of the cephalosporin C

A type by refluxing in aqueous solution with an excess of pyridine, for example, as described in Belgian Patent 593,777."

Likewise, there would be no question of the applicability of column 3, lines 47 to 50, if that sentence were introduced by the words "Any one of the compounds of Examples 1 to 15 is also readily converted into compounds of the C_A type * * *" or "Any one of the herein specifically named cephalosporin C compounds is also readily converted into compounds of the C_A type * * *."

Footnote 4. In re Ruschig, 52 CCPA 1238, 343 F.2d 965, 145 USPQ 274 (1965); In re Kalm, 54 CCPA 1466, 378 F.2d 959, 154 USPQ 10 (1967); In re McLamore, 54 CCPA 1544, 379 F.2d 985, 154 USPQ 114 (1967); and In re Ruschig, 54 CCPA 1551, 379 F.2d 990, 154 USPQ 118 (1967) (Ruschig II).

Footnote 5. Among the most recent of these are In re Ahlbrecht, 58 CCPA 848, 435 F.2d 908, 911, 168 USPQ 293, 296 (1971); In re Lukach, 58 CCPA 1233, 442 F.2d 967, 969, 169 USPQ 795, 796 (1971); and Fields v. Conover, 58 CCPA 1366, 443 F.2d 1386, 1391-92, 170 USPQ 276, 279-80 (1971).

Concurring Opinion Text

Concur By:

Baldwin, Judge, concurring, with whom Almond, Judge, joins.

While I agree that the disclosure in the Flynn patent is insufficient to constitute an anticipation of the claimed invention, I cannot agree with the language of the principal opinion that for the rejection based on an anticipation to have been proper, "the Flynn reference must clearly and unequivocally disclose the claimed compound or direct those skilled in the art to the compound without *any* need for picking, choosing, and combining various disclosures not directly related to each other by the teachings of the cited reference."

The test which determines whether an invention has been anticipated by a reference is whether the description of the invention in the reference is "sufficient to put the public in possession of the invention." In re LeGrice, 49 CCPA 1124, 1131, 301 F.2d 929, 933, 133 USPQ 365, 369 (1962), citing Curtis on Patents, 3d ed., Sec. 378 and Seymore v. Osborne, 78 U.S. (11 Wall.) 516, 555 (1870). See also In re Brown, 51 CCPA 1254, 329 F.2d 1006, 141 USPQ 245 (1964); In re Sheppard, 52 CCPA 859, 339 F.2d 238, 144 USPQ 42 (1964); In re Bird, 52 CCPA 1290, 344 F.2d 979, 145 USPQ 418 (1965); In re Borst, 52 CCPA 1398, 345 F.2d 851, 145 USPQ 554 (1965); In re Baranauckas, 55 CCPA 1204, 395 F.2d 805, 158 USPQ 24 (1968); In re Hoeksema, 55 CCPA 1493, 399 F.2d 269, 158 USPQ 596 (1968); In re Wilder, 57 CCPA 1314, 429 F.2d 447, 166 USPQ 545 (1970); and In re Moore, 58 CCPA 1341, 444 F.2d 572, 170 USPQ 260 (1971). I find it unreasonable to assume that Judge Rich and Judge Lane intend to overrule this long line of cases sub silentio. If what they intend is merely to rephrase the accepted test so as to simplify its application, they have missed the mark.

The language used in the principal opinion would not in fact simplify the determination of the suitability of a reference as an anticipation under 35 U.S.C. 102. That language requires the tribunal to analyze the teachings of a reference to determine which are equivocal and which are unequivocal. It must also be determined which disclosures are directly related to each other by the teachings of the reference, thus making picking and choosing proper, and which disclosures are only indirectly related, or are not related at all. This is no simpler than reading the reference as a whole and determining what it fairly teaches to one of ordinary skill in the art.

The more important difficulty with the position taken in the principal opinion is that it misdirects the inquiry. It directs the tribunal to analyze the structure of the reference rather than its content. The

real question is not how logically the various disclosures in a reference are related to each other, it is rather *what the reference fairly teaches to one of ordinary skill in the art*, no matter how ineptly it does so. Of course, the more logically the reference is laid out the clearer will be its teachings and the easier will be the job of those who must interpret it. But the law requires us to determine whether the invention has been *identically* described, *not* whether it has been *logically* described by the reference.

The Flynn reference has been described in both the principal opinion and the dissent. I will therefore merely state what I would consider that reference fairly teaches to one of ordinary skill in the art. Flynn does disclose the cephalosporin C_A-type precursor of the instantly claimed C_A-type compound. The precursor is one of approximately 38 C-type compounds specifically disclosed. Flynn teaches how C-type compounds can be converted to C_C-type compounds by heating with water under acid conditions, or converted to C_A-type compounds by refluxing in an aqueous solution with an excess of a tertiary amine. Pyridine is specifically referred to as an example of a tertiary amine which will work, but a list of over 15 other tertiary amines is given. With regard to antibacterial effect, Flynn discloses that C_C-type compounds are not as good as C-type compounds, and C-type compounds are not as good as C_A-type compounds. As pointed out by the dissent, Flynn considered the C_C-type and C_A-type analogues of the specifically disclosed C-type compounds to be some of the compounds "available in accordance with the present invention."

I would not place as much weight as the dissent does on Flynn's statement that the C_C-type and C_A-type analogues were considered within the scope of the invention. Such statements in the specification regarding the breadth of the invention are generally too speculative to be given great weight. In the instant case, all that statement does is focus some additional attention on C_C-type compounds and C_A-type compounds. In my view, that attention is not a significant addition to the disclosure, since Flynn's remarks regarding the antibacterial activity of the compounds are sufficient to emphasize the C_A-type compounds as the most desirable. The difficulty is that Flynn gives 38 or so possible precursors and 15 or so tertiary amines which will react with those precursors to form C_A-type

Page 529

compounds. The Flynn disclosure, considered as a whole, does not sufficiently direct one skilled in the art to the claimed compound.

I disagree with the principal opinion on one last point. The opinion seems to suggest that we violate due process whenever we consider portions of a reference not specifically mentioned by the examiner or the board. I know of no requirement that the examiner and the board must list the sentences in the reference upon which they rely, nor can I see any sense in imposing such a requirement. All of the disclosure of a reference must be considered for what it fairly teaches one of ordinary skill in the art. In *re Meinhardt*, 55 CCPA 1000, 1004, 392 F.2d 273, 276, 157 USPQ 270, 272 (1968). As Judge Smith aptly stated in *Meinhardt*:

[T]he board relied on the same [reference] as the examiner to sustain the rejection. Assuming arguendo that the board relied on a portion of the [reference] ignored by the examiner, this could not constitute a new ground of rejection in view of *In re Azorlosa*, 44 CCPA 826, 241 F.2d 939, 113 USPQ 156 (1957), which holds, in pertinent part, that it is proper for the court and necessarily, the board, to consider everything that a reference discloses.

In *re Meinhardt*, supra, 55 CCPA at 1008-09, 392 F.2d at 280, 157 USPQ at 275. See also *In re Halley*, 49 CCPA 793, 296 F.2d 774, 132 USPQ 16 (1961); *In re Van Mater*, 52 CCPA 1076, 341

F.2d 117, 144 USPQ 421 (1965).

Dissenting Opinion Text

Dissent By:

Worley, Chief Judge, dissenting.

I cannot agree with the majority that cephaloridine is not "described" in the Flynn patent in the sense of 35 U.S.C. 102(e).

It cannot be said, of course, that cephaloridine per se is *explicitly* named by Flynn, but a clear implicit description is sufficient. In re Baranauckas, 43 CCPA 727, 228 F.2d 413, 108 USPQ 226 (1955). Reference to the Flynn disclosure will establish, I submit, that such a description exists in the present instance.

The principal opinion has set forth portions of the generic and more specific disclosure of Flynn relied on by the board. The class of cephalosporin compounds disclosed generically by Flynn may be divided into several groups, of which the groups designated as cephalosporin C type and cephalosporin C_A type (cephaloridine is a C_A type) are of particular interest here. ¹After observing that "in general, those compounds which possess the cephalosporin C_A nucleus are more effective antibacterially than those containing the cephalosporin C nucleus," Flynn goes on to name and describe several specific compounds having the cephalosporin C nucleus:

The following examples, together with the [15] operating examples appearing hereinafter, will illustrate the types of compounds available in accordance with the present invention:

[There follows a list of 24 specific 7-acylamidocephalosporanic acids, i.e., cephalosporin C type compounds. As noted by the board, two of the 15 operating examples referred to, examples 4 and 10, describe the potassium and sodium salts of 7-(2- ϕ -thienyl-acetamido) cephalosporanic acid (the sodium salt is known commercially as "cephalothin"). Appellant reacts that particular cephalosporanic acid with the tertiary amine pyridine to obtain the claimed cephalosporin C_A type compound, cephaloridine.]

and the like, including the cephalosporin C_A and cephalosporin C_C analogues thereof.

[Emphasis supplied.]

There can be no doubt from the above disclosure that Flynn regarded the cephalosporin C_A analogues of each of the mentioned cephalosporin C type compounds to form an integral part of his disclosed invention. In particular, it is evident that Flynn does explicitly disclose the cephalosporin C_A analogues of Examples 4 and 10. As to how to obtain those C_A analogues from cephalosporin C type compounds, he states that compounds of the cephalosporin C_A class "can be obtained by applying to appropriate 7-acylamidocephalosporanic acids the conversion procedures of Belgian Patent 593,777." Flynn had earlier stated, as pointed out by the board and majority here just what those "conversion procedres" are, viz., that "Cephalosporin C is also readily converted into compounds of the cephalosporin C_A type by refluxing in aqueous solution with an excess of pyridine, for example, as described in Belgian Patent 593,777." ²[Emphasis supplied.]

I think it is clear that Flynn directs one of ordinary skill in the art, who is interested in particular cephalosporin C_A analogues of the 37 or so cephalosporin C type compounds Flynn specifically discloses, to prepare them by reacting the appropriate 7-acylamido cephalosporanic acid with the particular tertiaryamine pyridine. Following those instructions, one of ordinary skill in this art would easily prepare the C_A(pyridine) analogue of the particular cephalosporin C type compound described in Examples 4 and 10, which analogue is cephaloridine. Each and every one of the C_A(pyridine) analogues of that relatively small number of cephalosporin C compounds has been effectively, or implicitly, described by Flynn. To be sure, appellant is claiming only one of them, but it is no less described than any of the others.

From what has been said of Flynn, it should be evident that there is no need in this case for those skilled in the art to resort to picking and choosing various disclosures unrelated to each other by the reference teachings, as the principal opinion implies. On the contrary, the disclosures of cephalosporin C compounds, cephalosporin C_A compounds, and how to make them are all interrelated by Flynn himself. It should also be evident that the reference itself contains the full equivalent of the board's "postulations", which are quoted in footnote 3 and later deprecated in the principal opinion. Finally, it should be evident that the rejection rationale as stated herein is substantially identical to-not a reformulation of-that expressed by the board.

The principal opinion also criticizes the board for reading into references "things that are not there." My difficulty with that position stems from its disregard for the "things"-or "blaze marks"-that *are* there. In my opinion, the majority is groping for reversible error where none exists. As far back as 40 years, and over the years since, it has been a firm principle that this court would not reverse decisions of the tribunals below in highly complex areas of technology unless manifest error was shown. See, e.g., *In re Wietzel*, 17 CCPA 1079, 39 F.2d 669, 5 USPQ 177 (1930); *In re Bertsch*, 30 CCPA 813, 132 F.2d 1014, 56 USPQ 379 (1942); *In re Stoll*, 34 CCPA 1058, 161 F.2d 241, 73 USPQ 440 (1947). Needless to say, such error has not been shown here.

Although the majority would undoubtedly disclaim the notion, I cannot help but feel that it is resolving doubt on the issue presented in favor of the applicants. In doing so, this court is not doing the applicants or the public any favor. Rather it is bestowing on the applicants a license to litigate of dubious validity at a time when, it is reliably estimated, 80% of contested patents are being held invalid in other federal courts. And the other sad result here is to take from the public that which is already theirs by imposing on them a monopoly that should not exist. Appellants have given the public nothing it had not already been given by Flynn. I would remind my colleagues that patents are not like party favors to be passed out at random. The enabling statutes established under the Constitution clearly require more than appellants have offered as a quid pro quo to the public in exchange for the monopoly the majority awards them.

I find no error in the board's decision, and would affirm.

Footnotes

Footnote 1. For purposes here, cephalosporin C Atype compounds differ from cephalosporin C type compounds in the R₁ substituent attached to the methyl group located at the 3 position of the basic cephalosporin (cephem) nucleus. The C_A type compounds have a tertiary amine attached to that methyl group, whereas the C type compounds have an acyloxy group so attached. See the formula and definitions under "The Rejection" portion of the principal opinion. Cephaloridine has a pyridine radical attached to the 3-methyl group.

Footnote 2. Belgian 593,777 does indeed disclose obtaining of "antibiotic substances which are transformation products of Cephalosporin C and are called Cephalosporin C A compounds" by "treatment of Cephalosporin C in aqueous solution

with a weak, tertiary base, for example pyridine, collidine or quinoline. If pyridine is used, the antibiotic obtained is called Cephalosporin C A(pyridine)."

- End of Case -

Contact customer relations at: customercare@bna.com or 1-800-372-1033

ISSN 1526-8535

Copyright © 2005, The Bureau of National Affairs, Inc.

[Copyright FAQs](#) | [Internet Privacy Policy](#) | [BNA Accessibility Statement](#) | [License](#)

Reproduction or redistribution, in whole or in part, and in any form, without express written permission, is prohibited
except as permitted by the BNA Copyright Policy. <http://www.bna.com/corp/index.html#V>

FULL TEXT OF CASES (USPQ FIRST SERIES)

Ex parte Humber, Bruderlein, and Asselin, 217 USPQ 265 (BdPatApp&Int 1981)

Ex parte Humber, Bruderlein, and Asselin, 217 USPQ 265 (BdPatApp&Int 1981)

Ex parte Humber, Bruderlein, and Asselin

(BdPatApp&Int)

217 USPQ 265

Opinion dated Nov. 13, 1981

U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences

Headnotes

PATENTS

1. Patentability — Composition of matter — (§ 51.30)

Consistent with *In re Holladay*, 199 USPQ 516, applicants may show improved results for their claimed compounds in comparison with compounds that are even more closely related than those of prior art relied upon by Examiner in order to rebut *prima facie* case.

Particular patents — Chlorinated Compounds

Humber, Bruderlein, and Asselin, 13-Chloro-Benzocycloheptapyridoisoquinoline Derivatives and Process Therefor, rejection of claims 1-3 and 5-9 reversed.

Case History and Disposition:

Page 265

Appeal from Art Unit 122.

Application for patent of Leslie G. Humber, Francois T. Bruderlein, and Andre A. Asselin, Serial No. 817,660, filed July 21, 1977. From decision rejecting claims 1-3 and 5-9, applicants appeal (Appeal No. 443-29). Reversed.

Attorneys:

John W. Routh, New York, N.Y., for appellant.

Judge:

Before Blech and Goldstein, Examiners-in-Chief, and Seidleck, Acting Examiner-in-Chief.

Opinion Text

Opinion By:

Blech, Examiner-in-Chief.

This is an appeal from the final rejection of claims 1 through 3 and 5 through 9, all the claims remaining in the case.

Representatives of the claimed invention are:

1. A compound of formula 1

Tabular, graphic, or textual material set at this point is not available. Please consult hard copy or call BNA PLUS at 1-800-452-7773 or 202-452-4323.

in which R is lower alkyl selected from the group consisting of straight chain alkyl having up to six carbon atoms and branched chain alkyl having up to four carbon atoms or R is cycloalkyl having 3-6 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof.

5. A method of producing neuroleptic effects in a mammal which comprises administering to said mammal an effective neuroleptic amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition for producing neuroleptic effects in a mammal comprising an effective neuroleptic amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The references cited by the Examiner are:

Table set at this point is not available. See table in hard copy or call BNA PLUS at 1-800-452-7773 or 202-452-4323.

Winthrop et al (Winthrop), J.O.C., 27, pp. 230-240, 1962.

Voith et al (Voith), Psychopharmacologia, 42, pp. 11-20, 1975.

Page 266

Humber et al (Humber II), Abstract of Papers, 167th ACS National Meeting, Los Angeles, Calif., March 31-April 5, 1974.

Bruderlein et al (Bruderlein II), J. Med. Chem., Vol. 18, pp. 185-188, 1975.

The appealed claims stand rejected for obviousness under 35 U.S.C. 103. The Examiner considers them to be unpatentable over Voith and Bruderlein II in view of Humber I and Winthrop.

The non-chlorinated analogs of the claimed compounds, specifically also of the preferred species wherein R in the formula above set forth is isopropyl (named "Butaclamol"), are known, as shown by Voith and Bruderlein II. It is the Examiner's position that the claimed 13-Cl substituted derivatives thereof would be prima facie obvious to the artisan in light of the teachings of Humber I and Winthrop and that this presumption of obviousness has not been adequately rebutted by the Declaration evidence

of record.

We cannot subscribe to the Examiner's holding. It is predicated on the assumption that chlorination, in general, is well known in the pharmaceutical art and since related compounds possessing neuroleptic properties are known to be useful in either their non-chlorinated or chlorinated forms that the claimed compounds are thus obvious. Such an assumption manifestly is bottomed on the proposition that the position in the molecule at which the chlorination occurs is inconsequential and of no significance. But such is contraindicated by the very art relied upon by the Examiner, as well as by the Voith Declaration under 37 CFR 1.132. Thus, from the teaching of Winthrop the artisan would favor the 14-Cl substituted compound inasmuch only its precursor is disclosed to have increased activity. The Voith Declaration, however, convincingly demonstrates unexpectedly significant improved results for the 13-chloro vis-a-vis the 9-Cl, 12-Cl and 14-Cl substituted compounds. Such clearly could not have been foreseen and rebuts the Examiner's basic premise of equivalency of chlorination no matter at which position it is effected.

[1] Of course we appreciate and are cognizant of the Examiner's contention that no improved results have been shown for the claimed chlorinated compounds vis-a-vis the non-chlorinated analog butaclamol. However, consistent with the holding by the court in *In re Holladay*, 584 F.2d 384, 199 USPQ 516 (CCPA 1978), appellants may show improved results for their claimed compounds in comparison with compounds which, in fact, are even closer related than those of the prior art relied upon by the Examiner in order to rebut the prima facie case. Consequently, the comparative showing vis-a-vis the other chlorinated compounds which are more similar to those claimed than the non-chlorinated derivatives is viable probative evidence which palpably must be held as refuting the presumption of obviousness engendered by the art.

Accordingly, the decision of the Examiner is reversed.

Reversed.

- End of Case -

Contact customer relations at: customercare@bna.com or 1-800-372-1033

ISSN 1526-8535

Copyright © 2005, The Bureau of National Affairs, Inc.

[Copyright FAQs](#) | [Internet Privacy Policy](#) | [BNA Accessibility Statement](#) | [License](#)

Reproduction or redistribution, in whole or in part, and in any form, without express written permission, is prohibited except as permitted by the BNA Copyright Policy. <http://www.bna.com/corp/index.html#V>
